Theravance appoints Michael W. Aguiar as president, CEO

Friday, August 8, 2014

Theravance has appointed Michael W. Aguiar as president and CEO effective August 15, and as a member of the board of directors effective immediately. Aguiar plans to continue to as Theravance’s senior vice president and chief financial officer until his replacement is identified and appointed. 

[Read More]

Elan announces transactions to transform the company

Wednesday, May 22, 2013

Elan, a biotechnology company based in Ireland, announced a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement, the dividend pass through, and the completed Tysabri transaction, will form a dynamic and unique business foundation for Elan in the years ahead.

[Read More]

FDA approves GSK’s Breo Ellipta to treat COPD

Friday, May 17, 2013

The FDA has approved GlaxoSmithKline and Theravance’s Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also approved to reduce exacerbations of COPD in patients with a history of exacerbations. 

[Read More]